Abstract:Abstract Background Cell metabolism, in addition to providing energy and biochemical building blocks, also regulates immune cell function. We have increased our understanding of how natural killer cells (NK cell) metabolism impacts human NK cell function; however, little is known about NK cell role and metabolic changes in autoimmune diseases. The dysfunctional NK cell phenotype observed in pathological settings linked to defective cell metabolism will give insights into the development of new therapies for inflammatory diseases. IBD is an autoimmune disease of unknown origin characterised by severe gut inflammation and increased risk of colorectal cancer. NK cells can augment autoimmune responses through their activation of adaptive immune response by interaction with macrophages, dendritic cells and T cells; therefore, it is essential to decipher NK cells function in IBD to propose novel therapeutic targets. In this study, we defined the phenotype and metabolic profile of NK cells isolated from peripheral blood of IBD patients. Methods Blood samples were obtained from healthy donors and IBD patients from whom written consent had been obtained. PBMC were isolated by Lymphoprep (Axis-Shield) gradient. PBMC were stained with a combination of cell surface receptors, intracellular cytokines, proteins and analysed by flow cytometry. Cells were either stained ex vivo or after overnight stimulation with cytokine combination IL-12 + IL-15 and in the presence or absence of mTORC1 inhibitor rapamycin. Changes in OxPhos or glycolysis were detected by XFp extracellular flux analyser (Agilent Technologies). Mitochondria mass and polarisation were measured by flow cytometry utilising MitoTracker Green and MitoTracker Red, respectively (ThermoFisher). Results NK cells from IBD patients have impaired mTORC1 activity (a key signalling pathway regulating cell metabolism), which is associated with increased expression of pro-inflammatory cytokines IL-17 and TNF-α. Patients NK cells have dysfunctional mitochondria characterised by reduced mitochondria mass, low membrane potential and limited OXPHOS and glycolysis. Furthermore, patients NK cells have limited IFNγ production, reduced TRAIL expression and defective capability of killing cancer cells. Conclusion Taken together, our results strongly imply that NK cells from IBD patients have a distinct bioenergetic programme that favours the increased production of pro-inflammatory cytokines. This might be an important unknown defect of NK cells in the regulation of inflammation in IBD that can be used for the development of new treatments. Further studies need to be conducted to identify the reason for the observed defects and determination of other key metabolic pathways involved in NK-cell function during IBD.

NAD+ Metabolism and Immune Regulation: New Approaches to Inflammatory Bowel Disease Therapies

The Role of Nicotinamide Adenine Dinucleotide in the Pathogenesis of Rheumatoid Arthritis: Potential Implications for Treatment

Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel Disease.

NAD+ Precursors and Intestinal Inflammation: Therapeutic Insights Involving Gut Microbiota

NAD+ metabolism-based immunoregulation and therapeutic potential

Targeting NAD+ Metabolism to Modulate Autoimmunity and Inflammation

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

NAD+ Metabolism, Metabolic Stress, and Infection

The Role of NAD+ and NAD+-Boosting Therapies in Inflammatory Response by IL-13

Epithelial NAD+ depletion drives mitochondrial dysfunction and contributes to intestinal inflammation

Alterations in Kynurenine and NAD+ Salvage Pathways during the Successful Treatment of Inflammatory Bowel Disease Suggest HCAR3 and NNMT as Potential Drug Targets

From Bacteria to Biomedicine: Developing Therapies Exploiting NAD+ Metabolism.

Potential Role of NK Cells in the Pathogenesis of Inflammatory Bowel Disease

NAD+ and Its Possible Role in Gut Microbiota: Insights on the Mechanisms by Which Gut Microbes Influence Host Metabolism

P104 Defective metabolism mediates NK cell dysfunction in inflammatory bowel disease (IBD)

Natural products targeting Nrf2/ARE signaling pathway in the treatment of inflammatory bowel disease

Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease

A metabolic constraint in the kynurenine pathway drives mucosal inflammation in IBD

Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule

Colonic Dysregulation of Major Metabolic Pathways in Experimental Ulcerative Colitis

NAD metabolism modulates inflammation and mitochondria function in diabetic kidney disease